Table 3.
Solutions | n | Weighted Mean Difference (95% Cl) | Index | Compared Control | Follow-up Periods | Reference |
---|---|---|---|---|---|---|
CHG | 3 | −1.20 (−0.23 to −2.16) | GI or MGI | Placebo | 6 months | [50] |
10 | −0.21 (−0.11 to −0.31) | GI | Baseline | 4 to 6 weeks | [46] | |
4 | −0.185 (−0.285 to −0.086) | GI | Placebo | 6 months | [16] | |
19 | −0.223 (−0.412 to −0.034) † | GI or MGI | Baseline | ≥ 4 weeks | [48] | |
8 | −0.32 (−0.42 to −0.23) | GI | Baseline | 6w, 3m, 6m | [49] | |
EO | 9 | −1.44 (−0.82 to −2.06) | GI or MGI | Placebo | 6 months | [50] |
2 | −0.133 (−0.194 to −0.072) | GI | Placebo | 6 months | [16] | |
8 | −0.537 (−0.764 to −0.311) | MGI | Placebo | 6 months | [16] | |
16 | −0.203 (−0.312 to −0.093) † | GI or MGI | Baseline | ≥ 4 weeks | [48] | |
2 | −0.36 (−0.26 to −0.62) | GI | 21.6 or 26.9% hydro-alcohol | 6 months | [52] | |
11 | −0.52 (−0.67 to −0.37) | MGI | Placebo | 6 months | [51] | |
3 | −0.24 (−0.46 to −0.01) | GI | Placebo | 6 months | [51] | |
CPC (>0.05%) | 2 | −1.04 (0.06 to −2.14) * | GI or MGI | Placebo | 6 months | [50] |
5 | −0.70 (−0.83 to −0.57) | GI | Placebo | ≥ 6 weeks | [54] | |
3 | −0.344 (−0.627 to −0.062) | GI | Placebo | 6 months | [16] | |
2 | −0.357 (−0.483 to −0.231) | MGI | Placebo | 6 months | [16] | |
8 | −0.126 (−0.312 to 0.059) *,† | GI or MGI | Baseline | ≥ 4 weeks | [48] | |
CPC (≤0.05%) | 3 | −0.31 (0.76 to −1.38) * | GI or MGI | Placebo | 6 months | [50] |
Del | 1 | −0.06 (1.86 to −1.98) * | GI or MGI | Placebo | 6 months | [50] |
2 | −0.038 (−0.145 to −0.069) * | MGI | Placebo | 6 months | [16] | |
3 | −0.014 (−2.337 to 2.308) †,* | GI or MGI | Baseline | ≥ 4 weeks | [48] | |
AmF/SnF AmF/SnF |
1 | −0.76 (0.72 to −2.25) * | GI or MGI | Placebo | 6 months | [50] |
2 | −0.248 (−0.427 to −0.069) | GI | Placebo | 6 months | [16] | |
Alexi | 1 | −0.16 (1.77 to −2.09) * | GI or MGI | Placebo | 6 months | [50] |
Tric | 3 | −1.50 (−0.36 to −2.62) | GI or MGI | Placebo | 6 months | [50] |
Herb | 6 | −0.15 (−0.32 to 0.01) * | GI | CHG | 4 weeks | [57] |
5 | −0.09 (−0.25 to 0.08) * | GI | CHG | 12 weeks | [57] | |
3 | −0.28 (−0.51 to −0.06) | GI | Placebo | 3 w or 3 m | [59] | |
3 | −0.59 (−1.08 to −0.11) | MGI | Placebo | 2 to 4 weeks | [59] | |
5 | −0.07 (−0.22 to 0.07) * | GI | CHG | 2 to 4 w | [59] | |
Curcumin | 6 | −0.13 (−0.35 to 0.09) * | GI | CHG | 21 or 28 days | [60] |
Green Tea | 5 | 0.43(−0.63 to 1.49) * | GI | CHG | 2 to 4 w | [63] |
ClO2 | 4 | −0.712 (−0.457 to −0.967) | GI | Placebo | 7 to 21 days | [33] |
n: number of studies, CHG: chlorhexidine gluconate, EO: essential oils (Listerine antiseptic), CPC: cetylpyridinium chloride. Del: delmopinol, AmF/SnF: amine fluoride/stannous fluoride, Alexi: alexidine, Tric: triclosan, GI: gingival index (Löe and Silness), MGI: modified gingival index. † Expressed as the summary relative difference, meaning a percentage change from the baseline. * There was no significant difference (p > 0.05).